XML 45 R47.htm IDEA: XBRL DOCUMENT
v3.19.3

Condensed Consolidating financial statements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Condensed Consolidating Statements of Operations | Condensed Consolidating Statements of Operations
For the three months ended September 30, 2019 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Patient services revenues |  | $ | — |  |  | $ | 1,761,235 |  |  | $ | 1,087,531 |  |  | $ | (67,597 | ) |  | $ | 2,781,169 |
Provision for uncollectible accounts |  | — |  |  | (2,728 | ) |  | (1,249 | ) |  | — |  |  | (3,977 | )
Net patient service revenues |  | — |  |  | 1,758,507 |  |  | 1,086,282 |  |  | (67,597 | ) |  | 2,777,192 |
Other revenues |  | 204,183 |  |  | 140,956 |  |  | 83,860 |  |  | (302,113 | ) |  | 126,886 |
Total net revenues |  | 204,183 |  |  | 1,899,463 |  |  | 1,170,142 |  |  | (369,710 | ) |  | 2,904,078 |
Operating expenses |  | 11,046 |  |  | 1,823,752 |  |  | 1,060,654 |  |  | (369,710 | ) |  | 2,525,742 |
Operating income |  | 193,137 |  |  | 75,711 |  |  | 109,488 |  |  | — |  |  | 378,336 |
Debt expense |  | (110,712 | ) |  | (43,535 | ) |  | (14,206 | ) |  | 58,622 |  |  | (109,831 | )
Other income, net |  | 51,150 |  |  | 2,994 |  |  | 9,758 |  |  | (58,622 | ) |  | 5,280 |
Income tax expense |  | 33,364 |  |  | 28,320 |  |  | 3,570 |  |  | — |  |  | 65,254 |
Equity earnings in subsidiaries |  | 43,059 |  |  | 123,186 |  |  | — |  |  | (166,245 | ) |  | — |
Net income from continuing operations |  | 143,270 |  |  | 130,036 |  |  | 101,470 |  |  | (166,245 | ) |  | 208,531 |
Net loss from discontinued operations, net of tax |  | — |  |  | — |  |  | (6,843 | ) |  | — |  |  | (6,843 | )
Net income |  | 143,270 |  |  | 130,036 |  |  | 94,627 |  |  | (166,245 | ) |  | 201,688 |
Less: Net income attributable to noncontrolling interests |  | — |  |  | — |  |  | — |  |  | (58,418 | ) |  | (58,418 | )
Net income attributable to DaVita Inc. |  | $ | 143,270 |  |  | $ | 130,036 |  |  | $ | 94,627 |  |  | $ | (224,663 | ) |  | $ | 143,270 |
For the three months ended September 30, 2018 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Patient service revenues |  | $ | — |  |  | $ | 1,699,109 |  |  | $ | 1,028,548 |  |  | $ | (56,956 | ) |  | $ | 2,670,701 |
Provision for uncollectible accounts |  | — |  |  | (9,246 | ) |  | (2,731 | ) |  | — |  |  | (11,977 | )
Net patient service revenues |  | — |  |  | 1,689,863 |  |  | 1,025,817 |  |  | (56,956 | ) |  | 2,658,724 |
Other revenues |  | 207,968 |  |  | 127,269 |  |  | 136,448 |  |  | (283,079 | ) |  | 188,606 |
Total net revenues |  | 207,968 |  |  | 1,817,132 |  |  | 1,162,265 |  |  | (340,035 | ) |  | 2,847,330 |
Operating expenses and charges |  | 205,324 |  |  | 1,649,128 |  |  | 1,043,875 |  |  | (340,035 | ) |  | 2,558,292 |
Operating income |  | 2,644 |  |  | 168,004 |  |  | 118,390 |  |  | — |  |  | 289,038 |
Debt expense |  | (127,353 | ) |  | (50,254 | ) |  | (10,570 | ) |  | 62,250 |  |  | (125,927 | )
Other income, net |  | 106,148 |  |  | 603 |  |  | 7,719 |  |  | (110,463 | ) |  | 4,007 |
Income tax (benefit) expense |  | (3,536 | ) |  | 43,583 |  |  | 12,000 |  |  | — |  |  | 52,047 |
Equity earnings in subsidiaries |  | (121,771 | ) |  | 60,448 |  |  | — |  |  | 61,323 |  |  | — |
Net (loss) income from continuing operations |  | (136,796 | ) |  | 135,218 |  |  | 103,539 |  |  | 13,110 |  |  | 115,071 |
Net loss from discontinued operations, net of tax |  | — |  |  | — |  |  | (259,952 | ) |  | 48,213 |  |  | (211,739 | )
Net (loss) income |  | (136,796 | ) |  | 135,218 |  |  | (156,413 | ) |  | 61,323 |  |  | (96,668 | )
Less: Net income attributable to noncontrolling interests |  | — |  |  | — |  |  | — |  |  | (40,128 | ) |  | (40,128 | )
Net (loss) income attributable to DaVita Inc. |  | $ | (136,796 | ) |  | $ | 135,218 |  |  | $ | (156,413 | ) |  | $ | 21,195 |  |  | $ | (136,796 | )
For the nine months ended September 30, 2019 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Patient services revenues |  | $ | — |  |  | $ | 5,181,017 |  |  | $ | 3,164,726 |  |  | $ | (195,357 | ) |  | $ | 8,150,386 |
Provision for uncollectible accounts |  | — |  |  | (13,530 | ) |  | (6,159 | ) |  | — |  |  | (19,689 | )
Net patient service revenues |  | — |  |  | 5,167,487 |  |  | 3,158,567 |  |  | (195,357 | ) |  | 8,130,697 |
Other revenues |  | 600,318 |  |  | 438,058 |  |  | 130,345 |  |  | (809,523 | ) |  | 359,198 |
Total net revenues |  | 600,318 |  |  | 5,605,545 |  |  | 3,288,912 |  |  | (1,004,880 | ) |  | 8,489,895 |
Operating expenses and charges |  | 315,169 |  |  | 5,106,307 |  |  | 2,892,570 |  |  | (1,004,880 | ) |  | 7,309,166 |
Operating income |  | 285,149 |  |  | 499,238 |  |  | 396,342 |  |  | — |  |  | 1,180,729 |
Debt expense |  | (389,203 | ) |  | (145,110 | ) |  | (39,807 | ) |  | 188,944 |  |  | (385,176 | )
Other income, net |  | 263,407 |  |  | 4,332 |  |  | 31,800 |  |  | (281,676 | ) |  | 17,863 |
Income tax expense |  | 41,017 |  |  | 122,633 |  |  | 34,288 |  |  | — |  |  | 197,938 |
Equity earnings in subsidiaries |  | 447,774 |  |  | 318,431 |  |  | — |  |  | (766,205 | ) |  | — |
Net income from continuing operations |  | 566,110 |  |  | 554,258 |  |  | 354,047 |  |  | (858,937 | ) |  | 615,478 |
Net income from discontinued operations, net of tax |  | — |  |  | — |  |  | 10,122 |  |  | 92,732 |  |  | 102,854 |
Net income |  | 566,110 |  |  | 554,258 |  |  | 364,169 |  |  | (766,205 | ) |  | 718,332 |
Less: Net income attributable to noncontrolling interests |  | — |  |  | — |  |  | — |  |  | (152,222 | ) |  | (152,222 | )
Net income attributable to DaVita Inc. |  | $ | 566,110 |  |  | $ | 554,258 |  |  | $ | 364,169 |  |  | $ | (918,427 | ) |  | $ | 566,110 |
For the nine months ended September 30, 2018 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Patient services revenues |  | $ | — |  |  | $ | 5,100,487 |  |  | $ | 3,039,056 |  |  | $ | (159,365 | ) |  | $ | 7,980,178 |
Provision for uncollectible accounts |  | — |  |  | (26,430 | ) |  | (9,408 | ) |  | — |  |  | (35,838 | )
Net patient service revenues |  | — |  |  | 5,074,057 |  |  | 3,029,648 |  |  | (159,365 | ) |  | 7,944,340 |
Other revenues |  | 608,850 |  |  | 355,055 |  |  | 512,025 |  |  | (836,543 | ) |  | 639,387 |
Total net revenues |  | 608,850 |  |  | 5,429,112 |  |  | 3,541,673 |  |  | (995,908 | ) |  | 8,583,727 |
Operating expenses and charges |  | 484,329 |  |  | 4,949,070 |  |  | 3,008,320 |  |  | (995,908 | ) |  | 7,445,811 |
Operating income |  | 124,521 |  |  | 480,042 |  |  | 533,353 |  |  | — |  |  | 1,137,916 |
Debt expense |  | (362,501 | ) |  | (151,373 | ) |  | (30,660 | ) |  | 185,399 |  |  | (359,135 | )
Other income, net |  | 315,573 |  |  | 2,864 |  |  | 20,981 |  |  | (328,835 | ) |  | 10,583 |
Income tax expense |  | 24,108 |  |  | 112,193 |  |  | 70,351 |  |  | — |  |  | 206,652 |
Equity earnings in subsidiaries |  | 255,681 |  |  | 328,042 |  |  | — |  |  | (583,723 | ) |  | — |
Net income from continuing operations |  | 309,166 |  |  | 547,382 |  |  | 453,323 |  |  | (727,159 | ) |  | 582,712 |
Net loss from discontinued operations, net of tax |  | — |  |  | — |  |  | (291,265 | ) |  | 143,436 |  |  | (147,829 | )
Net income |  | 309,166 |  |  | 547,382 |  |  | 162,058 |  |  | (583,723 | ) |  | 434,883 |
Less: Net income attributable to noncontrolling interests |  | — |  |  | — |  |  | — |  |  | (125,717 | ) |  | (125,717 | )
Net income attributable to DaVita Inc. |  | $ | 309,166 |  |  | $ | 547,382 |  |  | $ | 162,058 |  |  | $ | (709,440 | ) |  | $ | 309,166 |
Condensed Consolidating Statements of Income
For the nine months ended September 30, 2019 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Patient service operating revenues |  | $ | 8,150,386 |  |  | $ | — |  |  | $ | — |  |  | $ | 8,150,386 |
Provision for uncollectible accounts |  | (19,689 | ) |  | — |  |  | — |  |  | (19,689 | )
Net patient service operating revenues |  | 8,130,697 |  |  | — |  |  | — |  |  | 8,130,697 |
Other revenues |  | 359,198 |  |  | — |  |  | — |  |  | 359,198 |
Total net operating revenues |  | 8,489,895 |  |  | — |  |  | — |  |  | 8,489,895 |
Operating expenses |  | 7,309,166 |  |  | — |  |  | — |  |  | 7,309,166 |
Operating income |  | 1,180,729 |  |  | — |  |  | — |  |  | 1,180,729 |
Debt expense |  | (385,176 | ) |  | — |  |  | — |  |  | (385,176 | )
Other income |  | 17,863 |  |  | — |  |  | — |  |  | 17,863 |
Income tax expense |  | 197,938 |  |  | — |  |  | — |  |  | 197,938 |
Net income from continuing operations |  | 615,478 |  |  | — |  |  | — |  |  | 615,478 |
Net income from discontinued operations, net of tax |  | 102,854 |  |  | 12,706 |  |  | 249 |  |  | 89,899 |
Net income |  | 718,332 |  |  | 12,706 |  |  | 249 |  |  | 705,377 |
Less: Net income attributable to noncontrolling interests |  | (152,222 | ) |  | (1,255 | ) |  | — |  |  | (150,967 | )
Net income attributable to DaVita Inc. |  | $ | 566,110 |  |  | $ | 11,451 |  |  | $ | 249 |  |  | $ | 554,410 |
(1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income | Condensed Consolidating Statements of Comprehensive Income
For the three months ended September 30, 2019 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Net income |  | $ | 143,270 |  |  | $ | 130,036 |  |  | $ | 94,627 |  |  | $ | (166,245 | ) |  | $ | 201,688 |
Other comprehensive income (loss) |  | 509 |  |  | — |  |  | (44,502 | ) |  | — |  |  | (43,993 | )
Total comprehensive income |  | 143,779 |  |  | 130,036 |  |  | 50,125 |  |  | (166,245 | ) |  | 157,695 |
Less: Comprehensive income attributable to noncontrolling interest |  | — |  |  | — |  |  | — |  |  | (58,418 | ) |  | (58,418 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 143,779 |  |  | $ | 130,036 |  |  | $ | 50,125 |  |  | $ | (224,663 | ) |  | $ | 99,277 |
For the three months ended September 30, 2018 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Net (loss) income |  | $ | (136,796 | ) |  | $ | 135,218 |  |  | $ | (156,413 | ) |  | $ | 61,323 |  |  | $ | (96,668 | )
Other comprehensive income (loss) |  | 1,643 |  |  | — |  |  | (8,827 | ) |  | — |  |  | (7,184 | )
Total comprehensive (loss) income |  | (135,153 | ) |  | 135,218 |  |  | (165,240 | ) |  | 61,323 |  |  | (103,852 | )
Less: Comprehensive income attributable to noncontrolling interest |  | — |  |  | — |  |  | — |  |  | (40,128 | ) |  | (40,128 | )
Comprehensive (loss) income attributable to DaVita Inc. |  | $ | (135,153 | ) |  | $ | 135,218 |  |  | $ | (165,240 | ) |  | $ | 21,195 |  |  | $ | (143,980 | )
For the nine months ended September 30, 2019 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Net income |  | $ | 566,110 |  |  | $ | 554,258 |  |  | $ | 364,169 |  |  | $ | (766,205 | ) |  | $ | 718,332 |
Other comprehensive income (loss) |  | 3,110 |  |  | — |  |  | (45,790 | ) |  | — |  |  | (42,680 | )
Total comprehensive income |  | 569,220 |  |  | 554,258 |  |  | 318,379 |  |  | (766,205 | ) |  | 675,652 |
Less: Comprehensive income attributable to noncontrolling interest |  | — |  |  | — |  |  | — |  |  | (152,222 | ) |  | (152,222 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 569,220 |  |  | $ | 554,258 |  |  | $ | 318,379 |  |  | $ | (918,427 | ) |  | $ | 523,430 |
For the nine months ended September 30, 2018 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Net income |  | $ | 309,166 |  |  | $ | 547,382 |  |  | $ | 162,058 |  |  | $ | (583,723 | ) |  | $ | 434,883 |
Other comprehensive income (loss) |  | 5,499 |  |  | — |  |  | (39,475 | ) |  | — |  |  | (33,976 | )
Total comprehensive income |  | 314,665 |  |  | 547,382 |  |  | 122,583 |  |  | (583,723 | ) |  | 400,907 |
Less: Comprehensive income attributable to noncontrolling interest |  | — |  |  | — |  |  | — |  |  | (125,717 | ) |  | (125,717 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 314,665 |  |  | $ | 547,382 |  |  | $ | 122,583 |  |  | $ | (709,440 | ) |  | $ | 275,190 |
Condensed Consolidating Statements of Comprehensive Income
For the nine months ended September 30, 2019 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Net income |  | $ | 718,332 |  |  | $ | 12,706 |  |  | $ | 249 |  |  | $ | 705,377 |
Other comprehensive income |  | (42,680 | ) |  | — |  |  | — |  |  | (42,680 | )
Total comprehensive income |  | 675,652 |  |  | 12,706 |  |  | 249 |  |  | 662,697 |
Less: Comprehensive income attributable to the noncontrolling interests |  | (152,222 | ) |  | (1,255 | ) |  | — |  |  | (150,967 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 523,430 |  |  | $ | 11,451 |  |  | $ | 249 |  |  | $ | 511,730 |
(1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets | Condensed Consolidating Balance Sheets
As of September 30, 2019 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Cash and cash equivalents |  | $ | 831,514 |  |  | $ | 213,635 |  |  | $ | 208,107 |  |  | $ | — |  |  | $ | 1,253,256 |
Restricted cash and equivalents |  | — |  |  | 14,444 |  |  | 89,441 |  |  | — |  |  | 103,885 |
Accounts receivable, net |  | — |  |  | 1,221,169 |  |  | 680,056 |  |  | — |  |  | 1,901,225 |
Other current assets |  | 161,548 |  |  | 455,616 |  |  | 123,188 |  |  | — |  |  | 740,352 |
Total current assets |  | 993,062 |  |  | 1,904,864 |  |  | 1,100,792 |  |  | — |  |  | 3,998,718 |
Property and equipment, net |  | 515,952 |  |  | 1,576,140 |  |  | 1,327,146 |  |  | — |  |  | 3,419,238 |
Operating lease right-of-use assets |  | 103,621 |  |  | 1,592,472 |  |  | 1,085,195 |  |  | — |  |  | 2,781,288 |
Intangible assets, net |  | 85 |  |  | 34,493 |  |  | 83,088 |  |  | — |  |  | 117,666 |
Investments in and advances to affiliates, net |  | 10,465,104 |  |  | 7,110,581 |  |  | 3,074,784 |  |  | (20,650,469 | ) |  | — |
Other long-term assets and investments |  | 96,953 |  |  | 91,115 |  |  | 181,193 |  |  | — |  |  | 369,261 |
Goodwill |  | — |  |  | 4,818,001 |  |  | 1,947,658 |  |  | — |  |  | 6,765,659 |
Total assets |  | $ | 12,174,777 |  |  | $ | 17,127,666 |  |  | $ | 8,799,856 |  |  | $ | (20,650,469 | ) |  | $ | 17,451,830 |
Current liabilities |  | $ | 313,934 |  |  | $ | 1,233,054 |  |  | $ | 659,652 |  |  | $ | — |  |  | $ | 2,206,640 |
Intercompany liabilities, net |  | 922,571 |  |  | 3,074,785 |  |  | 2,572,810 |  |  | (6,570,166 | ) |  | — |
Long-term operating leases liabilities |  | 131,743 |  |  | 1,508,343 |  |  | 1,042,039 |  |  | — |  |  | 2,682,125 |
Long-term debt and other long-term liabilities |  | 7,746,653 |  |  | 664,470 |  |  | 343,360 |  |  | — |  |  | 8,754,483 |
Noncontrolling interests subject to put provisions |  | 741,300 |  |  | — |  |  | — |  |  | 554,759 |  |  | 1,296,059 |
Total DaVita Inc. shareholders' equity |  | 2,318,576 |  |  | 10,647,014 |  |  | 3,433,289 |  |  | (14,080,303 | ) |  | 2,318,576 |
Noncontrolling interests not subject to put provisions |  | — |  |  | — |  |  | 748,706 |  |  | (554,759 | ) |  | 193,947 |
Total equity |  | 2,318,576 |  |  | 10,647,014 |  |  | 4,181,995 |  |  | (14,635,062 | ) |  | 2,512,523 |
Total liabilities and equity |  | $ | 12,174,777 |  |  | $ | 17,127,666 |  |  | $ | 8,799,856 |  |  | $ | (20,650,469 | ) |  | $ | 17,451,830 |
As of December 31, 2018 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Cash and cash equivalents |  | $ | 60,653 |  |  | $ | 1,232 |  |  | $ | 261,153 |  |  | $ | — |  |  | $ | 323,038 |
Restricted cash and equivalents |  | 1,005 |  |  | 12,048 |  |  | 79,329 |  |  | — |  |  | 92,382 |
Accounts receivable, net |  | — |  |  | 1,204,122 |  |  | 654,486 |  |  | — |  |  | 1,858,608 |
Other current assets |  | 37,185 |  |  | 565,974 |  |  | 157,407 |  |  | — |  |  | 760,566 |
Current assets held for sale |  | — |  |  | — |  |  | 5,389,565 |  |  | — |  |  | 5,389,565 |
Total current assets |  | 98,843 |  |  | 1,783,376 |  |  | 6,541,940 |  |  | — |  |  | 8,424,159 |
Property and equipment, net |  | 491,462 |  |  | 1,584,321 |  |  | 1,317,886 |  |  | — |  |  | 3,393,669 |
Intangible assets, net |  | 153 |  |  | 42,896 |  |  | 75,797 |  |  | — |  |  | 118,846 |
Investments in and advances to affiliates, net |  | 13,522,198 |  |  | 6,196,801 |  |  | 2,498,545 |  |  | (22,217,544 | ) |  | — |
Other long-term assets and investments |  | 53,385 |  |  | 90,037 |  |  | 188,196 |  |  | — |  |  | 331,618 |
Goodwill |  | — |  |  | 4,806,939 |  |  | 2,035,021 |  |  | — |  |  | 6,841,960 |
Total assets |  | $ | 14,166,041 |  |  | $ | 14,504,370 |  |  | $ | 12,657,385 |  |  | $ | (22,217,544 | ) |  | $ | 19,110,252 |
Current liabilities |  | $ | 1,945,943 |  |  | $ | 1,217,526 |  |  | $ | 483,933 |  |  | $ | — |  |  | $ | 3,647,402 |
Current liabilities held for sale |  | — |  |  | — |  |  | 1,243,759 |  |  | — |  |  | 1,243,759 |
Intercompany liabilities, net |  | — |  |  | 2,498,545 |  |  | 6,161,292 |  |  | (8,659,837 | ) |  | — |
Long-term debt and other long-term liabilities |  | 7,918,581 |  |  | 687,443 |  |  | 580,028 |  |  | — |  |  | 9,186,052 |
Noncontrolling interests subject to put provisions |  | 598,075 |  |  | — |  |  | — |  |  | 526,566 |  |  | 1,124,641 |
Total DaVita Inc. shareholders' equity |  | 3,703,442 |  |  | 10,100,856 |  |  | 3,456,851 |  |  | (13,557,707 | ) |  | 3,703,442 |
Noncontrolling interests not subject to put provisions |  | — |  |  | — |  |  | 731,522 |  |  | (526,566 | ) |  | 204,956 |
Total equity |  | 3,703,442 |  |  | 10,100,856 |  |  | 4,188,373 |  |  | (14,084,273 | ) |  | 3,908,398 |
Total liabilities and equity |  | $ | 14,166,041 |  |  | $ | 14,504,370 |  |  | $ | 12,657,385 |  |  | $ | (22,217,544 | ) |  | $ | 19,110,252 |
Condensed Consolidating Balance Sheets
As of September 30, 2019 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Cash and cash equivalents |  | $ | 1,253,256 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,253,256 |
Restricted cash and equivalents |  | 103,885 |  |  | — |  |  | — |  |  | 103,885 |
Accounts receivable, net |  | 1,901,225 |  |  | — |  |  | — |  |  | 1,901,225 |
Other current assets |  | 740,352 |  |  | — |  |  | — |  |  | 740,352 |
Total current assets |  | 3,998,718 |  |  | — |  |  | — |  |  | 3,998,718 |
Property and equipment, net |  | 3,419,238 |  |  | — |  |  | — |  |  | 3,419,238 |
Operating lease right-of-use assets |  | 2,781,288 |  |  | — |  |  | — |  |  | 2,781,288 |
Amortizable intangibles, net |  | 117,666 |  |  | — |  |  | — |  |  | 117,666 |
Other long-term assets |  | 369,261 |  |  | — |  |  | — |  |  | 369,261 |
Goodwill |  | 6,765,659 |  |  | — |  |  | — |  |  | 6,765,659 |
Total assets |  | $ | 17,451,830 |  |  | $ | — |  |  | $ | — |  |  | $ | 17,451,830 |
Current liabilities |  | $ | 2,206,640 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,206,640 |
Long-term operating leases liabilities |  | 2,682,125 |  |  | — |  |  | — |  |  | 2,682,125 |
Long-term debt and other long-term liabilities |  | 8,754,483 |  |  | — |  |  | — |  |  | 8,754,483 |
Noncontrolling interests subject to put provisions |  | 1,296,059 |  |  | — |  |  | — |  |  | 1,296,059 |
Total DaVita Inc. shareholders’ equity |  | 2,318,576 |  |  | — |  |  | — |  |  | 2,318,576 |
Noncontrolling interests not subject to put provisions |  | 193,947 |  |  | — |  |  | — |  |  | 193,947 |
Shareholders’ equity |  | 2,512,523 |  |  | — |  |  | — |  |  | 2,512,523 |
Total liabilities and shareholder’s equity |  | $ | 17,451,830 |  |  | $ | — |  |  | $ | — |  |  | $ | 17,451,830 |
(1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows | Condensed Consolidating Statements of Cash Flows
For the nine months ended September 30, 2019 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Cash flows provided by operating activities: |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 566,110 |  |  | $ | 554,258 |  |  | $ | 364,169 |  |  | $ | (766,205 | ) |  | $ | 718,332 |
Changes in operating assets and liabilities and non-cash items included in net income |  | (336,223 | ) |  | (74,600 | ) |  | 318,111 |  |  | 766,205 |  |  | 673,493 |
Net cash provided by operating activities |  | 229,887 |  |  | 479,658 |  |  | 682,280 |  |  | — |  |  | 1,391,825 |
Cash flows provided by (used in) investing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (106,476 | ) |  | (218,839 | ) |  | (221,868 | ) |  | — |  |  | (547,183 | )
Acquisitions |  | — |  |  | (11,832 | ) |  | (65,516 | ) |  | — |  |  | (77,348 | )
Proceeds (purchases) from asset and business sales |  | 3,824,516 |  |  | (244 | ) |  | 39,347 |  |  | — |  |  | 3,863,619 |
purchases from investment sales and other items, net |  | (94,322 | ) |  | (7,474 | ) |  | (3,267 | ) |  | — |  |  | (105,063 | )
Net cash provided by (used in) investing activities |  | 3,623,718 |  |  | (238,389 | ) |  | (251,304 | ) |  | — |  |  | 3,134,025 |
Cash flows used in financing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt and related financing costs, net |  | (2,028,954 | ) |  | (8,025 | ) |  | (13,033 | ) |  | — |  |  | (2,050,012 | )
Intercompany borrowings (payments) |  | 785,450 |  |  | (14,854 | ) |  | (770,596 | ) |  | — |  |  | — |
Other items |  | (1,840,245 | ) |  | (3,591 | ) |  | (109,916 | ) |  | — |  |  | (1,953,752 | )
Net cash used in financing activities |  | (3,083,749 | ) |  | (26,470 | ) |  | (893,545 | ) |  | — |  |  | (4,003,764 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | — |  |  | — |  |  | (4,178 | ) |  | — |  |  | (4,178 | )
Net increase (decrease) in cash, cash equivalents and restricted cash |  | 769,856 |  |  | 214,799 |  |  | (466,747 | ) |  | — |  |  | 517,908 |
Less: Net decrease in cash, cash equivalents and restricted cash from discontinued operations |  | — |  |  | — |  |  | (423,813 | ) |  | — |  |  | (423,813 | )
Net increase (decrease) in cash, cash equivalents and restricted cash from continuing operations |  | 769,856 |  |  | 214,799 |  |  | (42,934 | ) |  | — |  |  | 941,721 |
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 61,658 |  |  | 13,280 |  |  | 340,482 |  |  | — |  |  | 415,420 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 831,514 |  |  | $ | 228,079 |  |  | $ | 297,548 |  |  | $ | — |  |  | $ | 1,357,141 |
For the nine months ended September 30, 2018 |  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
Cash flows provided by operating activities: |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 309,166 |  |  | $ | 547,382 |  |  | $ | 162,058 |  |  | $ | (583,723 | ) |  | $ | 434,883 |
Changes in operating assets and liabilities and non-cash items included in net income |  | (235,558 | ) |  | (104,179 | ) |  | 703,379 |  |  | 583,723 |  |  | 947,365 |
Net cash provided by operating activities |  | 73,608 |  |  | 443,203 |  |  | 865,437 |  |  | — |  |  | 1,382,248 |
Cash flows used in investing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (124,585 | ) |  | (296,028 | ) |  | (285,046 | ) |  | — |  |  | (705,659 | )
Acquisitions |  | — |  |  | (5,646 | ) |  | (107,880 | ) |  | — |  |  | (113,526 | )
Proceeds from asset and business sales |  | — |  |  | 55,035 |  |  | 80,233 |  |  | — |  |  | 135,268 |
Proceeds (purchases) from investment sales and other items, net |  | 32,345 |  |  | (2,295 | ) |  | (7,452 | ) |  | — |  |  | 22,598 |
Net cash used in investing activities |  | (92,240 | ) |  | (248,934 | ) |  | (320,145 | ) |  | — |  |  | (661,319 | )
Cash flows provided by (used in) financing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt and related financing costs, net |  | 866,537 |  |  | (8,601 | ) |  | (12,100 | ) |  | — |  |  | 845,836 |
Intercompany borrowings (payments) |  | 454,410 |  |  | (174,148 | ) |  | (280,262 | ) |  | — |  |  | — |
Other items |  | (1,154,921 | ) |  | (18,713 | ) |  | (95,541 | ) |  | — |  |  | (1,269,175 | )
Net cash provided by (used in) financing activities |  | 166,026 |  |  | (201,462 | ) |  | (387,903 | ) |  | — |  |  | (423,339 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | — |  |  | — |  |  | (5,790 | ) |  | — |  |  | (5,790 | )
Net increase (decrease) in cash, cash equivalents and restricted cash |  | 147,394 |  |  | (7,193 | ) |  | 151,599 |  |  | — |  |  | 291,800 |
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations |  | — |  |  | — |  |  | 270,565 |  |  | — |  |  | 270,565 |
Net increase (decrease) in cash, cash equivalents and restricted cash from continuing operations |  | 147,394 |  |  | (7,193 | ) |  | (118,966 | ) |  | — |  |  | 21,235 |
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 150,307 |  |  | 19,963 |  |  | 348,650 |  |  | — |  |  | 518,920 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 297,701 |  |  | $ | 12,770 |  |  | $ | 229,684 |  |  | $ | — |  |  | $ | 540,155 |
Condensed Consolidating Statements of Cash Flows
For the nine months ended September 30, 2019 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net income |  | $ | 718,332 |  |  | $ | 12,706 |  |  | $ | 249 |  |  | $ | 705,377 |
Changes in operating and intercompany assets and liabilities and non-cash items included in net income |  | 673,493 |  |  | (4,607 | ) |  | (249 | ) |  | 678,349 |
Net cash provided by operating activities |  | 1,391,825 |  |  | 8,099 |  |  | — |  |  | 1,383,726 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (547,183 | ) |  | (846 | ) |  | — |  |  | (546,337 | )
Acquisitions |  | (77,348 | ) |  | — |  |  | — |  |  | (77,348 | )
Proceeds from asset and business sales |  | 3,863,619 |  |  | — |  |  | — |  |  | 3,863,619 |
Investments and other items |  | (105,063 | ) |  | (1,882 | ) |  | — |  |  | (103,181 | )
Net cash provided by (used in) investing activities |  | 3,134,025 |  |  | (2,728 | ) |  | — |  |  | 3,136,753 |
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt |  | (2,050,012 | ) |  | — |  |  | — |  |  | (2,050,012 | )
Intercompany |  | — |  |  | (247,175 | ) |  | — |  |  | 247,175 |
Other items |  | (1,953,752 | ) |  | — |  |  | — |  |  | (1,953,752 | )
Net cash used in financing activities |  | (4,003,764 | ) |  | (247,175 | ) |  | — |  |  | (3,756,589 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | (4,178 | ) |  | — |  |  | — |  |  | (4,178 | )
Net increase (decrease) in cash, cash equivalents and restricted cash |  | 517,908 |  |  | (241,804 | ) |  | — |  |  | 759,712 |
Less: Net decrease in cash, cash equivalents and restricted cash from discontinued operations |  | (423,813 | ) |  | (241,804 | ) |  | — |  |  | (182,009 | )
Net increase in cash, cash equivalents and restricted cash from continuing operations |  | 941,721 |  |  | — |  |  | — |  |  | 941,721 |
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 415,420 |  |  | — |  |  | — |  |  | 415,420 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 1,357,141 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,357,141 |
(1) After elimination of the unrestricted subsidiaries and the physician groups.

X
- Definition Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_CondensedStatementOfComprehensiveIncomeTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration